I now have all the information I need. Let me compile the final authoritative review.

## Summary

ProteinVista introduces a compute-efficient 3D CNN that voxelizes full-atom protein structures at 1Å resolution and is pre-trained on ~500K AlphaFold2 structures. It demonstrates that full-atom 3D CNNs are practically viable with modern hardware, achieving strong results on structure-sensitive protein-ligand prediction tasks while using dramatically fewer compute resources than sequence-based models like ESM-2. The key empirical contribution is on BindingDB IC50 regression (R² = 0.69 vs. 0.60–0.61 for ESM-2 variants), and the paper is notable for its honest reporting of limitations (GO annotation underperformance, failure analysis by similarity).

## Strengths

- **The compute-efficiency result is striking and well-documented (Section 4.3):** ProteinVista pre-trains in 48 hours on 4 A100 GPUs vs. ~7 days on 128 H100 GPUs for ESM-2₆₅₀M. During fine-tuning, it processes 1,000 proteins in 20 seconds vs. 426 seconds for ESM-2₆₅₀M. Storage is 3 MB (sequences) vs. 75 GB (3D grids), an honestly reported trade-off. These are concrete, non-trivial practical advantages.

- **The IC50 regression result on BindingDB is genuinely strong (Table 2):** ProteinVista achieves R² = 0.69 vs. 0.60/0.61 for both ESM-2 variants, with Pearson r increasing from 0.78 to 0.83. This large, unambiguous improvement on a practically important task where fine-grained structural detail is expected to matter provides strong support for the paper's thesis.

- **The failure analysis is informative and honestly reported (Section 4.1, Figure 2):** Partitioning the test set by sequence identity, TM-score, and pLDDT gives a nuanced picture of *when* structure helps. The paper candidly reports that on low-confidence AlphaFold2 structures ProteinVista performs comparably to ESM-2, and on GO annotation (Section 3.4, Fmax 0.57 vs. 0.62) it underperforms ESM-2. This candor strengthens credibility.

- **Architecture choices are clearly motivated and well-ablated (Section 4.2, Figure 2e):** The adaptive boxing (64³–160³ grids), continuous-density voxelization, and component ablations isolate what matters. The finding that fine-tuning without augmentation has almost no effect (−0.1% R²) while inference-time multi-view averaging is essential (−6.4% for a single view) is an actionable insight.

- **The comparison setup is fair and carefully controlled (Section 3.1):** All models receive identical MolFormer embeddings, the same prediction head architecture, and the same hyperparameter search. The explicit admission that this simple pipeline "likely underestimates for all models the peak accuracy" is honest and appropriate.

- **Pre-training efficiency is independently informative (Sections 2.3, 4.2):** Pre-training on only ~500K structures (vs. ~250M sequences for ESM-2), combined with the Rosetta-only ablation showing only −1.0% relative R² drop, demonstrates that the structural signal carries significant information independently of the ESM-2 alignment.

## Weaknesses

### Fatal
None.

### Major
None.

### Minor

- **No variance or uncertainty estimates for main results (Tables 1, 2).** Only point estimates (accuracy, AUC, R², MCC) are reported without standard deviations, confidence intervals, or number of random seeds. This matters because several classification improvements in Table 1 are small (e.g., TSP accuracy: 90.8% vs. 89.3% — a 1.5% absolute gain). The reported p-values (p < 10⁻¹³ for TSP) compare prediction error distributions on the test set, not the stability of model training across runs. The IC50 result (R² 0.69 vs. 0.61) has a sufficiently large margin to withstand this concern, but the classification improvements would benefit from variance estimates to confirm they are not within training noise.

- **The rotation augmentation is limited to discrete 90° rotations (Section 2.4), while the paper claims broader robustness.** The augmentation samples from 7 discrete transformations: identity, mirror across three axes, or 90° rotation around three axes. The paper claims the model learns representations "less affected by arbitrary rotations" (line 81) and aims for "rotation-invariant predictions" (line 31). Robustness to 90° rotations does not imply robustness to arbitrary continuous rotations (e.g., 23° around an arbitrary axis). The inference-time multi-view averaging (5 random views) compensates for orientation dependence but does not validate arbitrary rotation robustness. The claims should be qualified, or the paper should demonstrate robustness to arbitrary rotations (e.g., by rotating test proteins by random angles and measuring prediction consistency). The ablation showing that disabling augmentation during fine-tuning changes R² by only −0.1% further suggests that the augmentation may not enforce as much rotational robustness as claimed.

- **The primary pre-training objective creates a framing tension (Section 2.3).** ProteinVista is pre-trained by contrastive alignment to ESM-2 embeddings, then compared *against* ESM-2 and claimed to outperform it. A model trained to match ESM-2's embedding space outperforming ESM-2 is a weaker headline than a purely structure-based model doing so. The Rosetta-only ablation (−1.0% relative R²) partially addresses this by showing the structural signal is doing most of the work, but this version is not the primary model. The contribution would be cleaner if the purely structural model were foregrounded more prominently.

- **Potential data leakage between pre-training and downstream evaluation is not addressed.** ProteinVista is pre-trained on >500K Swiss-Prot AlphaFold2 structures (Section 2.3). The paper does not describe any decontamination procedure to ensure that test set proteins (or their close homologs) were excluded from pre-training. The homology analysis in Section 4.1 provides partial reassurance (the gap persists even in low-identity bins), but does not directly address whether the exact same proteins appear in both sets.

### Trivial

- **The abstract claim is slightly overstated for ESP.** The abstract states ProteinVista "outperforms sequence transformers on three benchmarks." On ESP accuracy (Table 1), ProteinVista alone scores 91.8% vs. ESM-2₆₅₀M's 91.9% — essentially a tie. The claim holds for the ESM-ProteinVista ensemble (93.0%) and for TSP and IC50 individually, but should be qualified for the ESP benchmark when referring to ProteinVista alone.

## Nice-to-Haves

- Test robustness to continuous rotations by rotating test proteins by random (non-90°) angles and measuring prediction consistency — this would directly validate the rotation robustness claims.
- Describe the cropping strategy for structures exceeding 160³ more precisely (center-crop vs. random-crop) and its potential impact on binding site coverage.
- Report the number of random seeds used for fine-tuning, even if single runs are common in this domain.

## Removed Points

These points are flagged to be removed; treat them with caution.

- **Garbled voxelization formula (line 57):** The parser-rendered formula is garbled ("$\vec{v} = \exp(-\|\vec{v} - \vec{r}\|/\sigma^2)$"). This is a [parser artifact, not an author error](/rule: "REMOVE any criticism about ... garbled text ... or any other formatting artifact"). The mathematical intent (Gaussian density assignment per channel) is clear from context.
- **FLOPs vs. wall-clock time discrepancy:** The critic questions the 20% FLOPs reduction vs. 95% wall-clock-time reduction. The paper's explanation (CNN parallelization efficiency vs. transformer layer depth) is reasonable; implementation-level curiosity does not constitute a weakness.
- **"First compute-efficient full-atom 3D CNN" claim:** The critic questions novelty vs. prior 3D CNNs (3DCNN_MQA, DeepSite). The paper's claim is specifically qualified with "pre-trained on large-scale AlphaFold-2 structures," and the paper already cites and discusses these prior works (Section 1). This is not a fair criticism as stated.
- **Table 1 formatting / row naming confusion:** A minor presentational preference; the table is legible and the distinction between standard and optimized pipelines is clear.
- **Missing related work references:** Prohibited per hard rules — the reviewer cannot verify claims about missing citations without external sources.
- **Cropping strategy underspecification:** This minor architectural detail does not affect the core claims; moved to Nice-to-Haves.
- **Reproducibility nitpicks about hyperparameters and implementation details:** Standard concerns that do not affect the validity of results.

## Novel Insights

None beyond the paper's own contributions. The review confirms the paper's strengths (compute efficiency, IC50 result, honest failure analysis) and surfaced the rotation augmentation gap and variance-reporting omission as the two most actionable weaknesses, neither of which the paper itself identifies as limitations.

## Suggestions

1. **Add variance estimates** (standard deviations across 3–5 random seeds) to Tables 1 and 2. This would significantly strengthen the classification results, which currently have small margins.
2. **Test continuous rotation robustness** by rotating test proteins by random angles and measuring prediction consistency. Add as a panel in Figure 2e's ablation study.
3. **Explicitly describe decontamination** between the Swiss-Prot pre-training set and downstream test sets, or report any overlap statistics.
4. **Qualify the abstract** to reflect that ProteinVista alone ties with ESM-2₆₅₀M on ESP accuracy, while the ensemble outperforms.
5. **Foreground the Rosetta-only ablation model** more prominently to cleanly separate the "structure vs. sequence" comparison from the "trained using ESM-2 vs. ESM-2" comparison.

---

## Calibration Report

**Initial bracket (Round 1):** 5.5–7.0, based on comparison with anchors:

| Anchor | Path | Avg Score | Round | Itemized | Comparison |
|--------|------|-----------|-------|----------|------------|
| ProteinWorkshop | sTYuRVrdK3.md | 6.25 | 1 | Yes | Benchmark paper; ProteinVista has comparable positive weights (+5.43 vs. +5.23 max) and similar negative weights (−3.56 vs. −3.46), plus a substantive method with strong results. |
| ProteiNexus | iBAWiEjogY.md | 3.67 | 1 | Yes | Much weaker paper; has massive negatives (−12.61 data leakage, −9.97 low novelty) that ProteinVista lacks entirely. ProteinVista is clearly stronger. |
| Pre-train Seq/Struct/Surface | BEH4mGo7zP.md | 5.75 | 1 | Yes | ProteinVista has stronger positives (+5.43 vs. +6.55 max) but much weaker negatives (−3.56 vs. −6.47, −5.73). The IC50 win is unambiguous, unlike this anchor's "marginal improvements." ProteinVista is stronger. |
| AtomSurf | ARQIJXFcTH.md | 6.75 | 1 | Yes | Stronger positives (+6.81, +6.01) than ProteinVista (+5.43 max), but also a massive −10.71 novelty negative. ProteinVista is comparable but slightly below. |
| SaProt | 6MRm3G4NiU.md | 7.33 | 2 | Yes | Clearly stronger paper: +7.71 positive weight, extensive evaluations, very strong results. ProteinVista is below this level. |
| RNA 3D property prediction | 9htTvHkUhh.md | 6.33 | 2 | Yes | Much weaker negatives (−9.15, −8.93) and weaker positives (+2–3 range). ProteinVista is clearly stronger. |

**Final score rationale:** ProteinVista's weighted item profile sits between sTYuRVrdK3 (6.25) and ARQIJXFcTH (6.75). Its strongest positive (+5.43 for IC50) and strongest negative (−3.56 for rotation augmentation) bracket it above 6.25 (where negatives are comparable but positives are slightly weaker) and below 6.75 (which has +6.81 positives despite a massive −10.71 negative). The paper has no fatal flaws, the core IC50 result is robust, the compute advantage is well-documented, and the authors honestly report limitations. The main actionable weaknesses (variance reporting, rotation claim scope) are addressable.

## Score and Decision

MY FINAL SCORE: <score>6.5</score>
MY FINAL DECISION: <decision>Accept</decision>